Back to search
FDAFDA · Food and drugs·Recall number D-0194-2019

Trimix QM10 Papaverine 30 mg/Phentolamine 4 mg/Atropine 1 mg/PGE 150 mcg/mL Injectable, Pharm D Solutions, Houston, Texas --- NDC 69699-1352-05

Published November 7, 2018 · Recall initiated: September 10, 2018

Summary

FDA records drug Class II recall D-0194-2019, published November 7, 2018 and initiated September 10, 2018. Recalling firm: Pharm D Solutions, LLC; Status: Terminated; Reported quantity: 9 vials; Lot: Lot: 04262018:09 Discard by: 10/22/2018; 07022018:48 Discard by: 12/29/2018. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility

What to do

Voluntary: Firm initiated · Press Release

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Pharm D Solutions, LLC
Distributor
Nationwide
Lot
Lot: 04262018:09 Discard by: 10/22/2018; 07022018:48 Discard by: 12/29/2018
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Trimix QM10 Papaverine 30 mg/Phentolamine 4 mg/Atropine 1 mg/PGE 150 mcg/mL Injectable, Pharm D Solutions, Houston, Texas --- NDC 69699-1352-05 recalled?

Yes. FDA published recall D-0194-2019 on November 7, 2018. Reported hazard: Lack of Assurance of Sterility

What should I do if I have this product?

Voluntary: Firm initiated · Press Release